披衣菌感染诊断市场－全球产业规模、份额、趋势、机会和预测，按检测类型、感染类型、最终用户、地区和竞争情况划分，2020 年至 2030 年预测

2024 年全球衣原体感染诊断市值为 7.2133 亿美元，预计到 2030 年将达到 10.3167 亿美元，预测期内复合年增长率为 6.12%。沙眼衣原体是导致披衣菌感染的细菌，也是全球最常见的性传染感染 (STI) 原因之一。由于披衣菌感染通常无症状，因此经常无法确诊，导致不孕症、骨盆腔发炎等併发症，并增加其他感染的易感性。随着人们认识的提高和全球性传染感染负担的增加（尤其是 15 至 24 岁性活跃人群），对及时、准确诊断的需求也在增加。市场已采取技术创新来提高可及性和准确性，例如核酸扩增测试（NAAT），其高灵敏度已被认可。儘管依赖集中实验室，但目前的努力重点是透过即时诊断技术提高检测週转率并扩大覆盖范围，支持更广泛的公共卫生策略来控制感染。

关键市场驱动因素

披衣菌感染盛行率上升推动披衣菌感染诊断市场发展

主要市场挑战

诊断不足和缺乏认识

主要市场趋势

技术进步

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球衣原体感染诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依检测类型（培养检测、核酸扩增检测（NAAT）、直接萤光抗体检测、血清学检测等）
  • 依感染类型（生殖器披衣菌感染、直肠披衣菌感染、眼部披衣菌感染）
  • 按最终使用者（医院、专科诊所、诊断中心）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按测试类型
  • 按感染类型
  • 按最终用户
  • 按地区

第六章：北美衣原体感染诊断市场展望

• 市场规模和预测
• 市场占有率和预测

第七章：欧洲衣原体感染诊断市场展望

• 市场规模和预测
• 市场占有率和预测

第八章：亚太地区衣原体感染诊断市场展望

• 市场规模和预测
• 市场占有率和预测

第九章：南美衣原体感染诊断市场展望

• 市场规模和预测
• 市场占有率和预测

第 10 章：中东和非洲衣原体感染诊断市场展望

• 市场规模和预测
• 市场占有率和预测

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：竞争格局

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca
• Teva Pharmaceutical Industries Limited
• bioMerieux SA

第 14 章：策略建议

第15章调查会社について・免责事项

The Global Chlamydia Infection Diagnostics Market was valued at USD 721.33 million in 2024 and is projected to reach USD 1031.67 million by 2030, growing at a CAGR of 6.12% during the forecast period. Chlamydia trachomatis, the bacterium responsible for chlamydia infections, is one of the most widespread causes of sexually transmitted infections (STIs) globally. Due to its often asymptomatic nature, chlamydia frequently goes undiagnosed, leading to complications such as infertility, pelvic inflammatory disease, and increased vulnerability to other infections. As awareness grows and the global burden of STIs rises-particularly among sexually active individuals aged 15 to 24-demand for timely, accurate diagnostics has increased. The market has responded with technological innovations that enhance accessibility and accuracy, such as nucleic acid amplification tests (NAATs), which are recognized for their high sensitivity. Despite the reliance on centralized laboratories, ongoing efforts are focused on improving test turnaround and expanding reach through point-of-care technologies, supporting broader public health strategies to contain the infection.

Key Market Drivers

Rising Prevalence of Chlamydia Infections is Driving Chlamydia Infection Diagnostics Market

The increasing global incidence of chlamydia infections is a major force behind the growth of the diagnostics market. As one of the most commonly reported STIs worldwide, chlamydia poses a significant health risk-particularly among adolescents and young adults who often lack awareness or access to regular testing. The asymptomatic nature of the infection makes it difficult to detect early, increasing the likelihood of long-term reproductive health complications such as infertility and ectopic pregnancies. The heightened focus on routine screening, particularly in high-risk populations, has accelerated the demand for diagnostic tools capable of delivering rapid, accurate results. This has led to the development and deployment of innovative testing methods, bolstering early intervention efforts and supporting global STI control initiatives. Educational campaigns and increased testing infrastructure are further reinforcing the demand for reliable chlamydia diagnostic solutions.

Key Market Challenges

Underdiagnosis and Lack of Awareness

A persistent challenge in the chlamydia diagnostics market is the widespread underdiagnosis of the infection, largely due to its asymptomatic presentation in the majority of cases. Without noticeable symptoms, many individuals remain unaware they are infected and do not seek testing, allowing the disease to spread undetected. This issue is compounded by limited public knowledge about STI risks, as well as cultural stigma surrounding sexual health, which deters open discussion and testing. In some regions, inadequate healthcare infrastructure and insufficient provider emphasis on STI screening further restrict access to diagnostics. These systemic and societal barriers contribute to a gap between infection rates and testing volumes, limiting early treatment and increasing the burden of long-term health complications.

Key Market Trends

Technological Advancements

Advancements in molecular diagnostics are significantly shaping the chlamydia diagnostics market. NAATs, including PCR and LAMP, have become the benchmark for detecting the genetic material of Chlamydia trachomatis, offering unparalleled sensitivity and specificity. These methods enable early detection, which is critical for timely treatment and preventing transmission. Furthermore, smartphone-integrated diagnostic platforms are emerging as accessible, user-friendly tools that facilitate at-home testing. These innovations empower individuals to screen for STIs with greater privacy and convenience. In parallel, serological and antibody-based assays are being utilized to detect historical infections, contributing to epidemiological tracking and broader public health insights. The integration of nucleic acid and serological tests is enhancing diagnostic capability, paving the way for more comprehensive infection profiling and treatment planning.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc
• Quidel Corporation
• DiaSorin SpA
• AstraZeneca
• Teva Pharmaceutical Industries Limited
• bioMerieux SA

Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chlamydia Infection Diagnostics Market, By Test Type:

• Culture Test
• Nucleic Acid Amplification Test (NAAT)
• Direct Fluorescent Antibody Test
• Serology Test
• Other

Chlamydia Infection Diagnostics Market, By Type of Infections:

• Genital Chlamydia Infection
• Rectal Chlamydia Infection
• Ocular Chlamydia Infection

Chlamydia Infection Diagnostics Market, By End User:

• Hospitals
• Specialty Clinics
• Diagnostics Centre

Chlamydia Infection Diagnostics Market, By Region:

• North America
• Asia-Pacific
• Europe
• Middle East & Africa
• South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chlamydia Infection Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)
  • 5.2.2. By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
  • 5.2.3. By End User (Hospitals, Specialty Clinics, Diagnostics Centre)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Test Type
  • 5.3.2. By Type of Infections
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Chlamydia Infection Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Type of Infections
  • 6.2.3. By End User
  • 6.2.4. By Country
    • 6.2.4.1. United States Chlamydia Infection Diagnostics Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
      • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
      • 6.2.4.1.2.1. By Test Type
      • 6.2.4.1.2.2. By Type of Infections
      • 6.2.4.1.2.3. By End User
    • 6.2.4.2. Canada Chlamydia Infection Diagnostics Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
      • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
      • 6.2.4.2.2.1. By Test Type
      • 6.2.4.2.2.2. By Type of Infections
      • 6.2.4.2.2.3. By End User
    • 6.2.4.3. Mexico Chlamydia Infection Diagnostics Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
      • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
      • 6.2.4.3.2.1. By Test
      • 6.2.4.3.2.2. By Type of Infections
      • 6.2.4.3.2.3. By End User

7. Europe Chlamydia Infection Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Type of Infections
  • 7.2.3. By End User
  • 7.2.4. By Country
    • 7.2.4.1. France Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
      • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
      • 7.2.4.1.2.1. By Test Type
      • 7.2.4.1.2.2. By Type of Infections
      • 7.2.4.1.2.3. By End User
    • 7.2.4.2. Germany Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
      • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
      • 7.2.4.2.2.1. By Test Type
      • 7.2.4.2.2.2. By Type of Infections
      • 7.2.4.2.2.3. By End User
    • 7.2.4.3. United Kingdom Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
      • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
      • 7.2.4.3.2.1. By Test Type
      • 7.2.4.3.2.2. By Type of Infections
      • 7.2.4.3.2.3. By End User
    • 7.2.4.4. Italy Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
      • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
      • 7.2.4.4.2.1. By Test Type
      • 7.2.4.4.2.2. By Type of Infections
      • 7.2.4.4.2.3. By End User
    • 7.2.4.5. Spain Chlamydia Infection Diagnostics Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
      • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
      • 7.2.4.5.2.1. By Test Type
      • 7.2.4.5.2.2. By Type of Infections
      • 7.2.4.5.2.3. By End User

8. Asia Pacific Chlamydia Infection Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Type of Infections
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. China Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
      • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
      • 8.2.4.1.2.1. By Test Type
      • 8.2.4.1.2.2. By Type of Infections
      • 8.2.4.1.2.3. By End User
    • 8.2.4.2. India Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
      • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
      • 8.2.4.2.2.1. By Test Type
      • 8.2.4.2.2.2. By Type of Infections
      • 8.2.4.2.2.3. By End User
    • 8.2.4.3. South Korea Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
      • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
      • 8.2.4.3.2.1. By Test Type
      • 8.2.4.3.2.2. By Type of Infections
      • 8.2.4.3.2.3. By End User
    • 8.2.4.4. Japan Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
      • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
      • 8.2.4.4.2.1. By Test Type
      • 8.2.4.4.2.2. By Type of Infections
      • 8.2.4.4.2.3. By End User
    • 8.2.4.5. Australia Chlamydia Infection Diagnostics Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
      • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
      • 8.2.4.5.2.1. By Test Type
      • 8.2.4.5.2.2. By Type of Infections
      • 8.2.4.5.2.3. By End User

9. South America Chlamydia Infection Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Type of Infections
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Chlamydia Infection Diagnostics Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
      • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
      • 9.2.4.1.2.1. By Test Type
      • 9.2.4.1.2.2. By Type of Infections
      • 9.2.4.1.2.3. By End User
    • 9.2.4.2. Argentina Chlamydia Infection Diagnostics Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
      • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
      • 9.2.4.2.2.1. By Test Type
      • 9.2.4.2.2.2. By Type of Infections
      • 9.2.4.2.2.3. By End User
    • 9.2.4.3. Colombia Chlamydia Infection Diagnostics Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
      • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
      • 9.2.4.3.2.1. By Test Type
      • 9.2.4.3.2.2. By Type of Infections
      • 9.2.4.3.2.3. By End User

10. Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Type of Infections
  • 10.2.3. By End User
  • 10.2.4. By Country
    • 10.2.4.1. South Africa Chlamydia Infection Diagnostics Market Outlook
      • 10.2.4.1.1. Market Size & Forecast
      • 10.2.4.1.1.1. By Value
      • 10.2.4.1.2. Market Share & Forecast
      • 10.2.4.1.2.1. By Test Type
      • 10.2.4.1.2.2. By Type of Infections
      • 10.2.4.1.2.3. By End User
    • 10.2.4.2. Saudi Arabia Chlamydia Infection Diagnostics Market Outlook
      • 10.2.4.2.1. Market Size & Forecast
      • 10.2.4.2.1.1. By Value
      • 10.2.4.2.2. Market Share & Forecast
      • 10.2.4.2.2.1. By Test Type
      • 10.2.4.2.2.2. By Type of Infections
      • 10.2.4.2.2.3. By End User
    • 10.2.4.3. UAE Chlamydia Infection Diagnostics Market Outlook
      • 10.2.4.3.1. Market Size & Forecast
      • 10.2.4.3.1.1. By Value
      • 10.2.4.3.2. Market Share & Forecast
      • 10.2.4.3.2.1. By Test Type
      • 10.2.4.3.2.2. By Type of Infections
      • 10.2.4.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. F. Hoffmann-La Roche Ltd.
• 13.2. Abbott Laboratories
• 13.3. Hologic, Inc.
• 13.4. Becton, Dickinson and Company
• 13.5. Bio-Rad Laboratories, Inc
• 13.6. Quidel Corporation
• 13.7. DiaSorin SpA
• 13.8. AstraZeneca
• 13.9. Teva Pharmaceutical Industries Limited
• 13.10. bioMerieux SA

14. Strategic Recommendations

15. About us & Disclaimer